TTI-0102
An investigational treatment for Leigh Syndrome and Cystinosis.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify TTI-0102 wherever you encounter it, plus the key facts at a glance.
- Generic name
- TTI-0102
- Development code
- TTI-0102
- Drug class
- Cysteamine prodrug (cysteamine-pantetheine mixed disulfide)
- Manufacturer
- Thiogenesis Therapeutics
- How it's taken
- Powder mixed in water and taken by mouth, in a trial only
An investigational medicine from Thiogenesis Therapeutics, a San Diego company, taken by mouth as a powder dissolved in water[1][5].
- TTI-0102 is a prodrug: the gut breaks it down into cysteamine, the active ingredient of the cystinosis medicines Cystagon and Procysbi, plus pantothenic acid (vitamin B5)[5][8].
- A Phase 2a trial in Leigh syndrome spectrum (NCT06990984) is listed on ClinicalTrials.gov as not yet recruiting, and Thiogenesis said on October 22, 2026 that it plans to start the trial in the fourth quarter of 2026[1][5].
- Thiogenesis describes itself as a clinical-stage company, and TTI-0102 is available only in clinical studies[6][1].
We'll email you when the FDA acts on TTI-0102 and when new trials for the condition you pick open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where TTI-0102 fits
TTI-0102 is an experimental cysteamine prodrug from Thiogenesis Therapeutics, taken by mouth, that is set to be tested in a Phase 2a trial in Leigh syndrome spectrum[1][5].
- Leigh syndrome has no proven therapy, and its care is directed at each person's symptoms and is supportive, according to NORD[13].
- NORD describes thiamine (vitamin B1) as the most common treatment given for Leigh syndrome, and a high-fat, low-carbohydrate diet as sometimes recommended for pyruvate dehydrogenase complex deficiency, one cause of the disease[13].
- ClinicalTrials.gov also lists a Phase 2 study of sirolimus for Leigh syndrome at Children's Hospital of Philadelphia, enrolling by invitation[4].
- TTI-0102 has not been compared with sirolimus, thiamine or any other treatment, and the Leigh syndrome trial compares it only with a placebo[1].
- In nephropathic cystinosis, where cysteamine is the standard of care, TTI-0102 has no patient data yet and is entering a 7-day pilot in about 6 adults[5].
- The Leigh syndrome trial leaves out people taking taurine who will not stop it during the study, so a question to bring to a mitochondrial disease specialist is whether a person's current supplements and recent hospital stays would fit the trial[1].
How TTI-0102 works
Leigh syndrome is an inherited disease of the mitochondria, the parts of cells that make energy. Variants in more than 110 genes can cause it, and most of those genes help mitochondria produce energy, according to MedlinePlus Genetics[12]. Thiogenesis says high oxidative stress, damage from unstable molecules that builds up when mitochondria struggle, is a key feature of Leigh syndrome spectrum[10].
TTI-0102 is a disulfide, 2 sulfur-containing pieces joined together, that the gut splits into 2 molecules of cysteamine and 1 of pantothenic acid[5]. Thiogenesis says cysteamine drives cells to make cysteine, a building block of the antioxidant glutathione and of the amino acid taurine[10]. The company designed the prodrug to release cysteamine gradually, aiming for a lower peak level in the blood than immediate-release cysteamine, which it links to stomach side effects, and to allow once-a-day dosing[9][11].
These are the company's stated aims. Thiogenesis has not reported results showing that TTI-0102 changes the course of Leigh syndrome, and the Phase 2a trial's main measures are cysteamine levels and glutathione in the blood[1][5].
Clinical trial results
The Leigh syndrome trial (NCT06990984, sponsor code TTI-LSS-001) is a Phase 2a, partially randomized, placebo-controlled, dose-ranging study for people aged 5 to 55 with Leigh syndrome or a Leigh-like disorder[1]. ClinicalTrials.gov describes 3 parts run in order: a placebo-controlled first part with 12 adolescents and adults over 40kg, then open-label parts with 3 adults and 3 children weighing 25-40kg, and with 3 children weighing 20-25kg[1].
Its main measures are cysteamine levels in the blood and plasma glutathione from day 1 to day 84, with side effects compared against placebo as a secondary measure[1]. The registry lists an estimated enrollment of 18, a start of October 2026 and a primary completion of June 2027[1].
On September 21, 2026 Thiogenesis described the trial as about 9 adolescents and adults, two-thirds of them on TTI-0102 for 12 weeks, measuring glutathione and other markers of oxidative stress and energy production alongside patient-reported fatigue and daily functioning, with topline data expected in the second quarter of 2027[6].
The registry and the company give different sizes; the registry record was last updated on July 22, 2026, before the company's September description[1].
Thiogenesis's first patient study was a Phase 2 trial in MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), another mitochondrial disease, at Radboud University in the Netherlands and CHU Angers in France (NCT06644534)[9][2]. ClinicalTrials.gov lists it as completed in January 2026 with 9 participants, a 12-minute walk test as its main efficacy measure, and no results posted[2].
Thiogenesis reported at the Mitocon 2026 conference that patients on about 60mg/kg a day had a mean reduction of up to 10% in total score on the Modified Fatigue Impact Scale, a patient-reported fatigue questionnaire, compared with placebo[8]. The company called these interim data from an exploratory study, and its release does not report the walk test result[8]. The company describes the study as single-blind, while ClinicalTrials.gov describes it as double-blind[8][2].
In nephropathic cystinosis, the FDA issued a Study May Proceed letter on October 16, 2026 for an investigator-led pilot at Emory University and Children's Healthcare of Atlanta, in which about 6 adults switch from their usual cysteamine to once-daily TTI-0102 for 7 days[5]. Thiogenesis says safety and tolerability are the primary goals and white blood cell cystine over 24 hours is exploratory, while the ClinicalTrials.gov record (NCT07837726), posted in September 2026, lists white blood cell cystine as its primary measure[5][3].
Thiogenesis's September 21, 2026 release had described 24-hour cystine control as the primary goal[6]. Thiogenesis said the protocol will be revised to reflect FDA comments, and it expects topline data in the first quarter of 2027[5].
Main registered trial: NCT06990984 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
No safety results from people with Leigh syndrome exist yet, because the trial has not started enrolling[1]. In a Phase 1 study in 12 healthy volunteers in Australia, Thiogenesis reported that TTI-0102 was well tolerated at doses from 600mg to 2,400mg cysteamine-base equivalent, with no serious adverse events[11]. Thiogenesis reported that the only moderate side effect was abnormal skin odor in 3 people at the highest dose[11].
In the Phase 2 MELAS study in Europe, Thiogenesis reported in November 2025 that 4 patients under 50kg left the study because of dose-dependent side effects[9]. In January 2026 the company reported that fixed dosing caused gastrointestinal side effects and dropouts in lighter patients, and that dosing by body weight reduced them[8]. Thiogenesis has not published counts of each side effect, and said in November 2025 that individual data remained confidential pending possible publication[9].
The Leigh syndrome trial leaves out people with a history of pancreatitis, severe gastrointestinal disease including gastroparesis, confirmed or suspected raised pressure inside the skull, or a known or suspected allergy to the drug, among other rules[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking TTI-0102
Taken by mouth as a powder dissolved in water, in trials only[1][5]. ClinicalTrials.gov says participants in the Leigh syndrome trial take the study drug twice daily for 12 weeks, in groups set by body weight[1]. In the MELAS study, Thiogenesis reported that a weight-based dose of about 60mg/kg a day, given once a day, kept cysteamine in the blood over 24 hours[8]. The cystinosis pilot plans a single daily dose of 60mg/kg, give or take 5mg/kg[3]. Any approved dose would be set by an FDA label.
Development history
Thiogenesis reported Phase 1 results in healthy volunteers on May 18, 2022[11]. On June 11, 2025 the company announced FDA clearance of its investigational new drug application for a Phase 2a trial in Leigh syndrome spectrum, designed with Children's Hospital of Philadelphia[10]. Thiogenesis has moved the trial's start date more than once since that clearance, and its October 22, 2026 release names the fourth quarter of 2026[9][6][5].
Thiogenesis presented MELAS data at Mitocon 2026 on January 23, 2026[8]. On July 13, 2026 Thiogenesis announced that the FDA had granted TTI-0102 rare pediatric disease designation for Leigh syndrome[7]. On October 22, 2026 the company announced FDA clearance for the cystinosis pilot and repeated its plan to start the Leigh syndrome trial in the fourth quarter of 2026[5].
Explore Leigh Syndrome and Cystinosis trials
Other Leigh Syndrome & Cystinosis treatments
Common questions about TTI-0102
▸What is TTI-0102?
An investigational medicine from Thiogenesis Therapeutics, a San Diego company, taken by mouth as a powder dissolved in water[1][5]. TTI-0102 is a prodrug: the gut breaks it down into cysteamine, the active ingredient of the cystinosis medicines Cystagon and Procysbi, plus pantothenic acid (vitamin B5)[5][8]. A Phase 2a trial in Leigh syndrome spectrum (NCT06990984) is listed on ClinicalTrials.gov as not yet recruiting, and Thiogenesis said on October 22, 2026 that it plans to start the trial in the fourth quarter of 2026[1][5]. Thiogenesis describes itself as a clinical-stage company, and TTI-0102 is available only in clinical studies[6][1].
▸How does TTI-0102 work?
Leigh syndrome is an inherited disease of the mitochondria, the parts of cells that make energy. Variants in more than 110 genes can cause it, and most of those genes help mitochondria produce energy, according to MedlinePlus Genetics[12]. Thiogenesis says high oxidative stress, damage from unstable molecules that builds up when mitochondria struggle, is a key feature of Leigh syndrome spectrum[10].
TTI-0102 is a disulfide, 2 sulfur-containing pieces joined together, that the gut splits into 2 molecules of cysteamine and 1 of pantothenic acid[5]. Thiogenesis says cysteamine drives cells to make cysteine, a building block of the antioxidant glutathione and of the amino acid taurine[10]. The company designed the prodrug to release cysteamine gradually, aiming for a lower peak level in the blood than immediate-release cysteamine, which it links to stomach side effects, and to allow once-a-day dosing[9][11].
These are the company's stated aims. Thiogenesis has not reported results showing that TTI-0102 changes the course of Leigh syndrome, and the Phase 2a trial's main measures are cysteamine levels and glutathione in the blood[1][5].
▸What are the side effects of TTI-0102?
No safety results from people with Leigh syndrome exist yet, because the trial has not started enrolling[1]. In a Phase 1 study in 12 healthy volunteers in Australia, Thiogenesis reported that TTI-0102 was well tolerated at doses from 600mg to 2,400mg cysteamine-base equivalent, with no serious adverse events[11]. Thiogenesis reported that the only moderate side effect was abnormal skin odor in 3 people at the highest dose[11]. In the Phase 2 MELAS study in Europe, Thiogenesis reported in November 2025 that 4 patients under 50kg left the study because of dose-dependent side effects[9]. In January 2026 the company reported that fixed dosing caused gastrointestinal side effects and dropouts in lighter patients, and that dosing by body weight reduced them[8]. Thiogenesis has not published counts of each side effect, and said in November 2025 that individual data remained confidential pending possible publication[9]. The Leigh syndrome trial leaves out people with a history of pancreatitis, severe gastrointestinal disease including gastroparesis, confirmed or suspected raised pressure inside the skull, or a known or suspected allergy to the drug, among other rules[1].
▸How is TTI-0102 taken?
Taken by mouth as a powder dissolved in water, in trials only[1][5]. ClinicalTrials.gov says participants in the Leigh syndrome trial take the study drug twice daily for 12 weeks, in groups set by body weight[1]. In the MELAS study, Thiogenesis reported that a weight-based dose of about 60mg/kg a day, given once a day, kept cysteamine in the blood over 24 hours[8]. The cystinosis pilot plans a single daily dose of 60mg/kg, give or take 5mg/kg[3]. Any approved dose would be set by an FDA label.
▸Is TTI-0102 FDA approved?
TTI-0102 is currently in phase 2 clinical trials for Leigh Syndrome and Cystinosis. It has not yet received FDA approval.
▸Is TTI-0102 FDA approved for Leigh syndrome?
No. TTI-0102 is an experimental drug, and its Phase 2a Leigh syndrome trial is listed as not yet recruiting.
Maker: Thiogenesis Therapeutics.
FDA status: Rare pediatric disease designation for Leigh syndrome, announced by Thiogenesis on July 13, 2026.
Trial: NCT06990984, for ages 5 to 55.
Source: ClinicalTrials.gov NCT06990984 and Thiogenesis, July 13, 2026%20copy.pdf)
▸When will the TTI-0102 Leigh syndrome trial start?
Thiogenesis said on October 22, 2026 that it plans to start the trial in the fourth quarter of 2026.
Registry status: Not yet recruiting, with no sites listed.
Site named by Thiogenesis: Children's Hospital of Philadelphia, in June 2025.
Results: Thiogenesis expects topline data in the second quarter of 2027, and ClinicalTrials.gov lists an estimated primary completion of June 2027.
Source: Thiogenesis, October 22, 2026, Thiogenesis, September 21, 2026 and ClinicalTrials.gov NCT06990984
▸Is TTI-0102 the same as cysteamine?
No. TTI-0102 is a different molecule that the gut breaks down into 2 molecules of cysteamine and 1 of pantothenic acid (vitamin B5).
Approved cysteamine: Cystagon and Procysbi, taken by mouth for nephropathic cystinosis.
Form: TTI-0102 is a powder dissolved in water.
Source: Thiogenesis, October 22, 2026 and Thiogenesis, January 23, 2026
▸What did TTI-0102 show in MELAS?
Thiogenesis reported a mean reduction of up to 10% in a fatigue questionnaire score compared with placebo, at about 60mg/kg a day.
Study size: 9 people with MELAS in the Netherlands and France.
Status: Interim data reported by the company; ClinicalTrials.gov has no posted results.
Leigh syndrome: No results yet, because the trial has not started.
Source: Thiogenesis, January 23, 2026 and ClinicalTrials.gov NCT06644534
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- ClinicalTrials.gov. A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS). https://clinicaltrials.gov/study/NCT06990984
- ClinicalTrials.gov. A Study to Assess TTI-0102 vs Placebo in MELAS Patients. https://clinicaltrials.gov/study/NCT06644534
- ClinicalTrials.gov. Pilot Study of TTI-0102 in Cystinosis. https://clinicaltrials.gov/study/NCT07837726
- ClinicalTrials.gov. Sirolimus for Leigh Syndrome. https://clinicaltrials.gov/study/NCT06843811
- Thiogenesis Therapeutics · 2026-10-22. Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6ae4c83388eb625d1f0c2a8e_NR%20261022%20Thio%20Announces%20CYS%20IND%20Cleared.pdf
- Thiogenesis Therapeutics · 2026-09-21. Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6ad77a3ac8c539010663c32e_TTI%20NR%20290921%20AGM%20Corp%20Update.pdf
- Thiogenesis Therapeutics · 2026-07-13. Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6a62500633c3be7864c87e56_NR%20260713-%20Thio%20Announces%20RPD%20(F)%20copy.pdf
- Thiogenesis Therapeutics · 2026-01-23. Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/69780ca6e83119ff5fad40f1_TTI%20NR%20260123%20Thio%20-%20MELAS%20Mitocon%20Prst%20.pdf
- Thiogenesis Therapeutics · 2025-11-04. Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/690a854c8d168110027ad857_TTI%20NR%20%20251104%20MELAS%20Ph%202%20Interim%20(F).pdf
- Thiogenesis Therapeutics · 2025-06-11. Thiogenesis Announces FDA Clearance of its Investigational New Drug Application (IND) for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/685e22cb7776a0c941373045_TTI%20%20NR%20250611%20FDA%20Clearance%20Ph2a%20LSS%20(F).pdf
- Thiogenesis Therapeutics · 2022-05-18. Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102. https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/637a9069d600312795c334e9_press%20release%202.pdf
- MedlinePlus, National Library of Medicine. Leigh syndrome. https://medlineplus.gov/genetics/condition/leigh-syndrome/
- National Organization for Rare Disorders · 2016-03-16. Leigh Syndrome. https://rarediseases.org/rare-diseases/leigh-syndrome/